Drug Trial Radar · NCT05561140
Resolution of Sickle Cell Leg Ulcers With Voxelotor
Last checked: Nov 20, 2026Latest source record: Jul 9, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
88
Actual
Start
May 30, 2022
Primary completion
Jun 26, 2024
Study completion Oct 22, 2024
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Sep 30, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a Phase 3, multicenter, randomized, placebo-controlled study to evaluate the efficacy of voxelotor and standard of care for the treatment of leg ulcers in participants with sickle cell disease. The study is divided into a 5 study periods: Screening, Run-in, Randomized Treatment, Open-label Treatment, and Follow-up/End of Study (EOS). The study will be conducted in approximately 80 eligible participants at approximately 20 global clinical trial sites.
Conditions
- Sickle Cell Disease
- Leg Ulcers
Interventions
Voxelotor Oral TabletDrug
Synthetic small molecule supplied as 500 mg tablets, administered Orally
PlaceboOther
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Who Achieved Resolution of the Target Ulcers by Week 12 in Randomized Treatment PeriodTime frame: Through Week 12 of randomized treatment period
Locations
23 sites in 3 countries. Site status is shown where the registry gives one.
Esho Empresa De Servicos Hospitalares S.A/ Hospital Samaritano Higienopolis
São Paulo, Brazil
Hospital das Clínicas da Faculdade de Medicina da Universidade de Sao Paulo
São Paulo, Brazil
Hospital das Clínicas da Faculdade de Medicina da Universidade de Sao Paulo
São Paulo, Brazil
Complexo Hospitalar Universitário Professor Edgard Santos- Universidade Federal Da Bahia
Salvador, Estado de Bahia, Brazil
Universidade Federal Da Bahia Hospital Universitário Professor Edgard Santos
Salvador, Estado de Bahia, Brazil
Hospital São Rafael
Salvador, Estado de Bahia, Brazil
Hospital das Clinicas da Universidade Federal de Minas Gerais
Belo Horizonte, Minas Gerais, Brazil
Multihemo Servicos Medicos S/A
Recife, Pernambuco, Brazil
Hospital das Clínicas da Faculdade de Medicina da Universidade de Sao Paulo
Cerqueira Cesar - Sao Paulo, São Paulo, Brazil
Hospital das Clinicas da Faculdade de Medicina de Ribeirão Preto da Universidade de Sao Paulo
Ribeirão Preto, São Paulo, Brazil
KEMRI Kondele Children's Hospital within Jaramogi Oginga Odinga Teaching and Referral Hospital.
Kisumu, Kenya
Gertrude's Children's Hospital
Nairobi, Kenya
KEMRI-Centre for Respiratory Diseases Research-Nairobi
Nairobi, Kenya
Strathmore University Medical Centre
Nairobi, Kenya
KEMRI-CRDR, KEMRI Clinical Research Annex
Siaya, Kenya
KEMRI Centre for Clinical Research Butere County Hospital
Butere, Kakamega County, Kenya
Barau Dikko Teaching Hospital/Kaduna State University
Kaduna, Nigeria
Aminu kano Teaching Hospital
Kano, Nigeria
Lagos University Teaching Hospital
Lagos, Nigeria
SYNLAB
Gwagwalada, Abuja, Nigeria
University of Calabar Teaching Hospital
Calabar, Cross River State, Nigeria
SYNLAB
Abuja, Federal Capital Territory, Nigeria
University of Abuja Teaching Hospital
Gwagwalada, Federal Capital Territory, Nigeria
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.